Feedback / Questions
CTX-712 - Chordia Therap
https://www.prnewswire.com/news-releases/chordia-therapeutics-announces-interim-results-of-the-phase-1-clinical-trial-of-clk-inhibitor-ctx-712-at-the-2022-asco-annual-meeting-301562398.html
Jun 7, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next